Advertisement NIAID funds BioCryst's non-human primate trial of BCX4430 to treat Ebola disease - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

NIAID funds BioCryst’s non-human primate trial of BCX4430 to treat Ebola disease

BioCryst Pharmaceuticals has received an additional funding of $2.4m from the National Institute of Allergy and Infectious Diseases (NIAID) to conduct a study of an intramuscular formulation of BCX4430 in non-human primates to treat Ebola virus disease.

Scheduled to be initiated within weeks, the dose ranging efficacy trial in an experimental Ebola virus disease model in non-human primates represents a major step towards understanding the potential of BCX4430 as a treatment for Ebola disease in humans.

In September 2013, BioCryst secured a five-year $22m contract from NIAID, part of the National Institutes of Health (NIH).

With the additional funding, the BCX4430 development contract has been increased in value to $24.4m, if all options are exercised.

The development project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.

Main objective of the company’s BSAV research program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to health and national security.

BCX4430 is an RNA dependent-RNA polymerase inhibitor that has showed broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.